Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07911145
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
**PF-07911145** (also known as BNT167) is an investigational **mRNA-based prophylactic vaccine** developed by Pfizer in collaboration with BioNTech for the prevention of **varicella** (chickenpox) and potentially **herpes zoster** (shingles), caused by the varicella-zoster virus. It encodes viral antigens to induce immune responses, including neutralizing antibodies and T-cell immunity, against the herpesvirus. The vaccine advanced to **Phase 1** clinical trials but has since been **dropped** from further development.[5][7][9][13][15]
02
Targets
gE (VZV glycoprotein E)VZV glycoproteins (Varicella-zoster virus glycoproteins)VZV gH/gL (Varicella-zoster virus glycoprotein H/glycoprotein L complex)
Beyond the preview
Go deeper on PF-07911145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07911145.